Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

11 results
Display

Optic neuropathy associated with ethambutol in Koreans

Choi SY, Hwang JM

Ethambutol is a useful first line antituberculous drug, but can cause significant visual impairment. In order to determine the clinical manifestations of optic neuropathy associated with ethambutol, and the margin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Herbal Medication Aggravates Cataract Formation: A Case Report

Kang KD, Kang SM, Yim HB

We report a case of complicated cataract aggravated after taking herbal medication for atopic dermatitis. An 11-yr-old boy was referred for the evaluation of decreased visual acuity in both eyes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy

Lim JW, Ryu SJ, Shin MC

PURPOSE: To evaluate the effect of intravitreal bevacizumab injection (IVBI) in acute central serous chorioretinopathy (CSC) patients. METHODS: Patients with acute CSC received IVBI (1.25 mg/0.05 mL) or observation by...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization in Angioid Streaks

Lee JW, Shin JP, Kim SY

A 56-year-old Korean woman presented with decreased visual acuity of the right eye. She had a history of two photodynamic therapy treatments for choroidal neovascularization (CNV) due to angioid streaks...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early versus Late Intravitreal Triamcinolone Acetonide for Macular Edema associated with Branch Retinal Vein Occlusion

Oh JY, Seo JH, Ahn JK, Heo JW, Chung H

PURPOSE: To compare the effect of early versus late intravitreal injection of triamcinolone in patients with macular edema due to branch retinal vein occlusion (BRVO). METHODS: Twenty eyes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy

Entezari M, Ramezani A, Yaseri M

In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration

Lee KH, Chin HS, Kim NR, Moon YS

PURPOSE: To investigate the effects of vitreomacular traction (VMT) on ranibizumab treatment response for neovascular age-related macular degeneration (AMD). METHODS: A retrospective review of 85 eyes of 85 patients newly diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma

Mishra D, Sinha BP, Kumar MS

PURPOSE: To compare the efficacy and safety of latanoprost, bimatoprost, travoprost and timolol in reducing intraocular pressure (IOP) in patients with primary open angle glaucoma. METHODS: This was a prospective study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment

Ahn YJ, Hwang HB, Chung SK

Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab

Kim NR, Chin HS

A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps

Kim JH, Lee DW, Choi SC, Kim JW, Lee TG, Kim CG, Cho HJ

PURPOSE: To evaluate the 12-month outcome of anti-vascular endothelial growth factor (VEGF) treatment for extrafoveal polypoidal choroidal vasculopathy (PCV). METHODS: This retrospective observational study included 32 eyes of 32 patients newly...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr